WO2005115470A2 - COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS - Google Patents
COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS Download PDFInfo
- Publication number
- WO2005115470A2 WO2005115470A2 PCT/FR2005/001082 FR2005001082W WO2005115470A2 WO 2005115470 A2 WO2005115470 A2 WO 2005115470A2 FR 2005001082 W FR2005001082 W FR 2005001082W WO 2005115470 A2 WO2005115470 A2 WO 2005115470A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- day
- cancer
- compound
- harmalacidin
- harmine
- Prior art date
Links
- 0 *C1N(*)CCc2c1[n](*)c1c2ccc(*)c1 Chemical compound *C1N(*)CCc2c1[n](*)c1c2ccc(*)c1 0.000 description 1
- PSFDQSOCUJVVGF-UHFFFAOYSA-N Cc1nccc2c1[nH]c1ccccc21 Chemical compound Cc1nccc2c1[nH]c1ccccc21 PSFDQSOCUJVVGF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Definitions
- the present invention relates in particular to pharmaceutical compositions containing derivatives of ⁇ -carboline, an alkaloid, corresponding in particular to those extracted from Peganum harmala, such as harmine, harmane and harmalacidin, and their use in the context cancer treatment.
- Peganum harmala is used in traditional medicine in many conditions.
- Peganum alkaloids are known for their antibacterial, antifungal, antiviral, hypothermic properties and especially their hallucinogenic effects.
- a previous study demonstrated an anti-tumor activity of extracts of P. harmala seeds on rat and mouse tumors .
- the administration of a crude alkaloid extract of P. harmala seeds, at a dose of 50 mg / kg / day, orally caused grafted mouse tumors (subcutaneous) to disappear in 80% of the mice treated (Lamchouri et al.
- the present invention aims to provide pharmaceutical compositions comprising compounds derived from / 3-carboline for the preparation of medicaments intended for the treatment of cancers.
- Another object of the present invention is to provide another compound capable of entering into synergy with compounds derived from / 3-carboline for the preparation of medicaments intended for the treatment of cancers.
- - Ri represents H, OH, or an alkoxyl group of 1 to 12 carbon atoms
- - R 2 represents H, an alkoxycarbonyl group of 1 to 12 carbon atoms, in particular the tert-butoxycarbonyl group, or an alkyl group from 1 to 12 carbon atoms
- - R 3 represents O or CH, provided that when R 3 represents O, then a represents a double bond, b and c represent a single bond and Rt represents H, and that when R 3 represents CH 3 then a represents a single bond, b and c represent a double bond and P does not represent any group; or its pharmaceutically acceptable salts, for the preparation of a medicament intended for the treatment of cancers, such as colon cancers, leukemias, myelomas, breast cancers, neuroblastomas, hepatocarcinomas, lung cancers, prostate cancer, ovarian cancer, testicular cancer, gastric cancer, pancreatic cancer, or retinoblastoma.
- cancers
- At least one compound of general formula (1) is associated with at least one compound which inhibits DNA replication.
- “Compound inhibiting DNA replication” means any compound capable of inhibiting a stage of DNA replication, whether by inhibiting the activity of the enzymes involved in replication, such as DNA polymerases, topoisomerases, helicases, primases, ligases, or by binding or modifying DNA, for example by binding to two strands of DNA (such as alkylating agents), or by preventing the synthesis of thymidine.
- the association of a compound of general formula (1) with a compound which inhibits DNA replication has synergistic effects in the treatment of tumors.
- the compound of general formula (1) is advantageously used as an adjuvant intended to increase the effects of compounds inhibiting DNA replication in the context of the preparation of anti-tumor drugs.
- association means that the compound of general formula (1) and the DNA replication inhibiting compound are both present structurally independently in a drug or pharmaceutical composition according to the invention and that they are not linked together by strong chemical bonds of the covalent or coordination type.
- the pharmaceutically acceptable salts of the compounds of general formula (1) the hydrochloride salts are particularly preferred.
- the compound of general formula (1) corresponds: - to the compounds of formula (2) below, - or to the compounds of formula (3) below,
- the compound of general formula (1) corresponds to: - the harmony (4):
- harmine as well as harmalacidin has an anti-tumor action in vivo, in particular on human tumors. This action is enhanced when harmine and harmalacidin are administered in combination with a compound that inhibits DNA replication.
- the pharmaceutically acceptable salts of the compounds of formulas (4), (5) and (6) above can also be used according to the invention, and in particular harmine hydrochloride, harmane hydrochloride and hydrochloride d 'harmalacidine.
- ha ⁇ nane whose chemical structure is close to that of harmine, has a common cell target with harmine (Sobhani et al. (2002) J. Pharm. Pharmaceut. Sci. 5: 19-23).
- the compound inhibiting DNA replication is chosen from the group comprising: - an alkylating agent, such as cyclophosphamide, mitomycin C or thiotepa; - an antimetabolite, such as 5-fluorouracil, macaw C or methotrexate; - a platinum coordination complex, such as carboplatin or cisplatin; - or an agent inhibiting topoisomerase II, such as doxorubicin, mitoxantrone or amsacrine.
- alkylating agent such as cyclophosphamide, mitomycin C or thiotepa
- an antimetabolite such as 5-fluorouracil, macaw C or methotrexate
- - a platinum coordination complex such as carboplatin or cisplatin
- - or an agent inhibiting topoisomerase II such as doxorubicin, mitoxantrone or amsacrine.
- an alkylating agent acts by preventing the separation of the two DNA strands of the same fragment by carrying out a solid covalent bridging.
- An antimetabolite prevents either by taking the place of the bases (5-fluorouracil or ara-C), or by inhibiting the enzymatic synthesis of thymidine (5-fluorouracil, methotrexate).
- the platinum coordination complexes in particular carry out a solid bridging between the two DNA strands of the same fragment.
- Topoisomerase II has the activity of cutting and re-soldering the two DNA strands of the same fragment in the context of the relaxation of supercoiled DNA.
- this relates to the use as defined above, in which the molar amount of compound of general formula (1) is greater than the molar amount of the compound inhibiting the replication of the DNA associated with it.
- the molar quantity of compound of general formula (1) is less than 20% greater than the molar quantity of the compound which inhibits the replication of the DNA which is associated with it.
- it relates to the use as defined above of harmine or harmalacidin, and of cyclophosphamide.
- it relates to the use as defined above of harmine or harmalacidin, and of 5-fluorouracil.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising as active substance at least one compound of general formula (1), or one of its pharmaceutically acceptable salts, in combination with at least one compound inhibiting DNA replication and a vehicle pharmaceutically acceptable.
- the pharmaceutical composition is such that the compound of general formula (1) corresponds to: - the harmine (4):
- the pharmaceutical composition is such that the compound inhibiting DNA replication is chosen from the group comprising: - an alkylating agent, such as cyclophosphamide, mitomycin C or thiotepa ; - an antimetabolite, such as 5-fluorouracil, macaw C or methotrexate; - a platinum coordination complex, such as carboplatin or cisplatin; - or an agent inhibiting topoisomerase II, such as doxorubicin, mitoxantrone or amsacrine.
- the pharmaceutical composition according to the invention is suitable for administration by oral or intravenous route.
- the pharmaceutical composition according to the invention comprises, as active substance, harmine or harmalacidin, in combination with cyclophosphamide and a pharmaceutically acceptable vehicle.
- the abovementioned pharmaceutical composition is suitable for administration by the oral route: from approximately 1 to approximately 10 mg / kg / d of harmine, or from approximately 1 to approximately 5 mg / kg / d d of harmalacidin, and from about 1 to about 5 mg / kg / d of cyclophosphamide.
- the abovementioned pharmaceutical composition is suitable for administration by the intravenous route: from approximately 1 to approximately 3 mg / kg / d of harmonic acid, or from approximately 1 to approximately 3 mg / kg / d of harmonalacidin, and from about 1 to about 5 mg / kg / d of cyclophosphamide.
- the pharmaceutical composition according to the invention comprises, as active substance, harmine or harmalacidin, in combination with 5-fluorouracil and a pharmaceutically acceptable vehicle.
- the abovementioned pharmaceutical composition is suitable for administration by the oral route: from approximately 1 to approximately 10 mg / kg / d of harmine, or from approximately 1 to approximately 5 mg / kg / d d of harmonalacidin, and from approximately 1 to approximately 10 mg kg / d of 5-fluorouracil.
- the abovementioned pharmaceutical composition is suitable for administration by the intravenous route: from approximately 1 to approximately 3 mg / kg / d of harmonic acid, or from approximately 1 to approximately 3 mg / kg / d of harmonalacidin, and from about 1 to about 5 mg / kg / d of 5-fluorouracil.
- the pharmaceutical composition as defined above is suitable for the administration of a molar quantity of compound of general formula (1) greater than the molar quantity of the compound inhibiting the replication of the DNA which it is associated.
- the pharmaceutical composition is suitable for the administration of a molar quantity of compound of general formula (1) at least 20% greater than the molar quantity of the compound inhibiting the replication of the DNA which is associated with it.
- the present invention also relates to products containing - at least one compound of general formula (1), or one of its pharmaceutically acceptable salts, and - at least one compound which inhibits DNA replication, as combination products for simultaneous, separate or spread over time in the treatment of cancers, such as colon cancer, leukemia, myeloma, breast cancer, neuroblastoma, hepatocarcinoma, cancer lung, prostate cancer, ovarian cancer, testicular cancer, gastric cancer, pancreatic cancer, or retinoblastoma.
- cancers such as colon cancer, leukemia, myeloma, breast cancer, neuroblastoma, hepatocarcinoma, cancer lung, prostate cancer, ovarian cancer, testicular cancer, gastric cancer, pancreatic cancer, or retinoblastoma.
- the term "combination” means that the compound of general formula (1) and the DNA replication inhibiting compound are both structurally independent in the products according to the invention and that they are not linked to each other by strong chemical bonds of
- the combination products are such that the compound inhibiting DNA replication is chosen from the group comprising: - an alkylating agent, such as cyclophosphamide, mitomycin C or thiotepa; - an antimetabolite, such as 5-fluorouracil, macaw C or methotrexate; - a platinum coordination complex, such as carboplatin or cisplatin; - or an agent inhibiting topoisomerase II, such as doxorubicin, mitoxantrone or amsacrine.
- an alkylating agent such as cyclophosphamide, mitomycin C or thiotepa
- an antimetabolite such as 5-fluorouracil, macaw C or methotrexate
- - a platinum coordination complex such as carboplatin or cisplatin
- - or an agent inhibiting topoisomerase II such as doxorubicin, mitoxantrone or amsacrine.
- the invention relates to products as defined above, containing - harmine or harmalacidin, and - 5-fluorouracil, as combination products for simultaneous, separate use or spread over time as part of the treatment of cancers, such as colon cancer, breast cancer, hepatocarcinoma, lung cancer, prostate cancer, ovarian cancer, gastric cancer, or pancreatic cancers.
- cancers such as colon cancer, breast cancer, hepatocarcinoma, lung cancer, prostate cancer, ovarian cancer, gastric cancer, or pancreatic cancers.
- the invention relates to products as defined above, containing: - harmine or harmalacidin, and - cyclophosphamide, as combination products for simultaneous, separate or spread over time as part of the treatment of cancers, such as colon cancer, leukemia, myeloma, breast cancer, neuroblastoma, hepatocarcinoma, lung cancer, ovarian cancer, cancer of the testicle, or retinoblastomas.
- the products as defined above comprise a molar amount of compound of general formula (1) greater than the molar amount of the DNA replication inhibiting compound with which it is in combination.
- the products comprise a molar quantity of compound of general formula (1) at least 20% greater than the molar quantity of the DNA replication inhibiting compound with which it is combined.
- Figure 1 represents the evolution of the size of HT29 tumors (in cm 3 , ordinate axis) grafted on untreated NOD-SCID mice (diamonds), or treated with harmine at 100 mg / kg / day (cross), 125 mg / kg / day (squares), 150 mg / kg / day (triangles) or 175 mg / kg / day (circles) depending on time (in days, abscissa axis).
- Figure 2A represents the evolution of the size of HT29 tumors (in cm 3 , ordinate axis) grafted on untreated NOD-SCID mice (cross), or treated with cyclophosphamide at 50 mg / kg / day (triangles ), 100 mg / kg / day (squares), or by a mixture of harmine 100 mg / kg / day + cyclophosphamide 100 mg / kg / day (circles) or harmine 150 mg / kg / day + cyclophosphamide 50 mg / kg / day (diamonds) as a function of time (in days, x-axis).
- Figure 2B represents the evolution of the size of HT29 tumors (in cm 3 , ordinate axis) grafted on untreated NOD-SCID mice (diamonds), or treated with harmine at 150 mg / kg / day (triangles), cyclophosphamide at 50 mg / kg / day (cross), or by a harmine mixture at 150 mg / kg / day + cyclophosphamide at 50 mg / kg / day (circles) as a function of time (in days, axis abscissa).
- Figure 3A represents the evolution of the size of HT29 tumors (in cm 3 , ordinate axis) grafted on untreated NOD-SCID mice (circles), or treated with 5-fluorouracil at 3 mg / kg / day (triangles), 6 mg / kg / day (squares), 9 mg / kg / day (cross), 12 mg / kg / day (diamonds) or 24 mg / kg / day (dashes) as a function of time (in days, abscissa axis).
- Figure 3B represents the evolution of the size of HT29 tumors (in cm 3 , ordinate axis) grafted on untreated NOD-SCLD mice (triangles), or treated with harmine at 150 mg / kg / day (cross), 5-fluorouracil at 12 mg / kg / day (squares), or by a harmine mixture at 150 mg / kg / day + 5-fluorouracil at 12 mg / kg / day (circles) as a function of time (in days, abscissa axis).
- Figure 4 represents the evolution of the size of HT29 tumors (in cm 3 , ordinate axis) grafted on untreated (square) NOD-SCID mice, or treated with harmalacidin at 25 mg / kg / day (triangles) or at 50 mg / kg / day (cross), with cyclophosphamide at 50 mg / kg / day (diamonds), or by a harmalacidin mixture 25 mg / kg / day + cyclophosphamide 50 mg / kg / day (dashes ) or harmalacidin 50 mg / kg / day + cyclophosphamide 50 mg / kg / day (circles), as a function of time (in days, abscissa axis).
- Harmalacidin (C) the molecular mass of the hydrochloride dihydrate of harmonalacidin: M 288.
- cytotoxic effects of the various alkaloid extracts of P. harmala have been studied on several cell lines: - human leukemic cell lines: K562 and Jurkat (leukemia), U937 (myeloma), - human solid tumor cell lines: KB (nasopharyngeal epithelioma) and HT29 (colon), - immortalized endothelial cell lines of human bone marrow: HBMEC.
- the cells are cultured in an incubator under a 5% CO 2 atmosphere and at 37 ° C., in RPMI1640 medium for K562, Jurkat, U937 and HT29 and DMEM for KB, supplemented with 10% fetal calf serum, penicillin-streptomycin 0.01 % and 2 mM L-glutamine and in EGM2 medium for HBMEC cells.
- the cytotoxicity test is carried out in a 96-well microplate in the presence of the extract to be tested at various concentrations of 40, 20, 10, 5, 1, 0.5 ⁇ g / ml and in the absence of product, after a 4 day incubation at 37 ° C. On Day 3, we add a neutral red solution which is absorbed by living cells.
- the optical density (OD) of dye released by lysed cells is measured at 540 nm by an Elisa plate reader.
- the toxicity (% growth inhibition) is inversely proportional to the optical density.
- the percentage inhibition is defined as being the difference between the OD without product and the OD in the presence of product compared to the OD without product.
- the concentration inhibiting at 50% the cell growth is obtained from the curve representative of the percentage of inhibition as a function of the logarithm of the concentration. All the results obtained are collated in the following Table 1.
- the IC 5 o vis-à-vis the cancerous and endothelial cells tested is as follows: 5 to 12 ⁇ g / ml for the crude alkaloid extract, 2.9 to 4.6 ⁇ g / ml (14 - 22 ⁇ M) for the harmine, 3 to 10 ⁇ g / ml (10.5 - 35 ⁇ M) for harmine hydrochloride, and 10.5 to 29 ⁇ g / ml (34.4 - 134 ⁇ M) for harmalacidin hydrochloride.
- NOD-SCID having received a xenograft of human tumor cells.
- NOD-SCLO mice male and female, over 3 months old, were raised in an environment of strict sterility, in an isolator ventilated by filtered and sterilized air, at 22 ° C and 40% humidity, under a day-12h / night-12h cycle.
- the cages, bottles and water have been sterilized in an autoclave at 120 ° C for 30 minutes and the food and the litter are treated by ⁇ irradiation. All the manipulations were carried out aseptically under a laminar flow hood.
- the mice were subjected to general anesthesia by ip injection of 0.3 to 0.4 ml of hypnomidate 2 mg / ml.
- the harmine-inhibiting action on tumor growth was manifested in a dose-dependent manner between 125 to 175 mg.
- the dose of 100 mg / kg / day has a very weak effect.
- the dose of 125 mg / kg / day begins to show a significant effect: the tumor volume reaches 55 to 67% of the tumor volume of the untreated group.
- the tumor volume represents only 42% of that of the control group until day 50, but reached 51% in the 60 th day.
- the dose of 200 mg / kg / day was not tolerated, the mice died after a few days of treatment.
- 150 mg of cyclophosphamide (Sigma) were dissolved in 8 ml of water and the solution obtained was sterilized by filtration on a membrane with a porosity of 0.22 ⁇ m.
- the mice received either 50, 100, or 150 mg / kg / day of cyclophosphamide alone, or a harmine mixture 150 mg / kg / day + cyclophosphamide 50 mg / kg / day or harmine 100 mg / kg / day + cyclophosphamide 100 mg / kg / day.
- Table 3 Treatment with cyclophosphamide, alone or in combination with harmine, of mice xenografted with human tumor cells HT29
- Dose Group Dose Average volume of tumors of mice treated with cyclophosphamide harmine relative to the average volume of tumors of (mg / kg / day) (mg / kg / day) untreated mice (T / C) (%) Day 15 Day 30 Day 40 Day 50 Day 60 1 0 0 100 100 100 100 100 2 0 50 63 42 37 36 32 3 0 100 47 25 18 14 15 4 0 150 4 5 150 50 20 10 7 8 9 6 100 10 (3 36 16 11 10 9
- 50 mg of 5-fluorouracil (Sigma) were dissolved in 8 ml of water and the solution obtained was sterilized by filtration on a membrane with a porosity of 0.22 ⁇ m.
- the mice received either 3, 6, 9, 12, or 24 mg / kg / day of 5-fluorouracil alone, or a harmine mixture 150 mg / kg / day + 5-fluorouracil 12 mg / kg / day.
- the results obtained are presented in Table 4 and in Figures 3A and SB-
- mice xenografted with human tumor cells HT29 Dose Group
- Day 50 Day 60 1 0 0 100 100 100 100 100 100 2 0 3 43 56 66 61 86 3 0 6 37 53 60 64 70 4 0 9 41 41 59 52 59 5 0 12 73 66 54 47 59 6 0 24 17 54 54 7 150 12 25 26 22 21 23
- 5 -fluorouracil is delivered alone per os, at doses between 3 and
- Harmine 150 mg / kg / day was administered simultaneously in combination with increasing doses of 5-fluorouracil: 3, 6, 9 and 12 mg / kg / day respectively. Only the harmine 150 mg / kg / day + 5-fluorouracil 12 mg / kg / day association is given in Table 4 (harmine / 5-fluorouracil molar ratio of 7.7 / 1). This combination, administered in a 6-day treatment and 6-day rest cycle, has synergistic effects on the inhibition of tumor growth (Table 4, Figure 3B and was able to keep the tumor volume even less than 1.3 cm 3 on the 60 th day of treatment, with 23% T / C.
- Table 5 Treatment with harmalacidin, alone or in combination with cyclophosphamide, of mice xenografted with human tumor cells HT29 Group.
- Dose Average Volume Dose of Tumors of Cyclophosphamide Harmalacidin Mice Treated Relative to Average Volume of (mg / kg / day) (mg / kg / day) Tumors of Untreated Mice (T / C) (%) Day 15 Day 30 Day 40 Day 50 Day 60 1 0 0 100 100 100 100 100 100 100 100 2 25 0 81 72 70 65 77 3 50 0 42 56 48 45 57 4 100 0 death - - - - 5 25 50 45 29 26 23 25 6 50 50 60 32 24 20 20 20
- the 100 mg / kg / day dose was not supported for more than 10 days.
- Harmalacidin 25 or 50 mg / kg / day was administered simultaneously in combination with cyclophosphamide 50 mg / kg / day.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007510083A JP2007535525A (ja) | 2004-04-30 | 2005-04-29 | β−カルボリン誘導体を含有する医薬組成物および癌を処置するためのそれらの使用 |
EP05767476A EP1740212A2 (fr) | 2004-04-30 | 2005-04-29 | Compositions pharmaceutiques contenant des derives de betacarboline, et leur utilisation pour le traitement des cancers |
US11/587,852 US20080069899A1 (en) | 2004-04-30 | 2005-04-29 | Pharmaceutical Compositions Comprising Beta-Carboline Derivatives and Use Thereof for the Treatment of Cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR04/04646 | 2004-04-30 | ||
FR0404646A FR2869540B1 (fr) | 2004-04-30 | 2004-04-30 | Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005115470A2 true WO2005115470A2 (fr) | 2005-12-08 |
WO2005115470A3 WO2005115470A3 (fr) | 2007-03-22 |
Family
ID=34950528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2005/001082 WO2005115470A2 (fr) | 2004-04-30 | 2005-04-29 | COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080069899A1 (fr) |
EP (1) | EP1740212A2 (fr) |
JP (1) | JP2007535525A (fr) |
FR (1) | FR2869540B1 (fr) |
WO (1) | WO2005115470A2 (fr) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009078423A1 (fr) * | 2007-12-18 | 2009-06-25 | National University Corporation University Of Toyama | Composé tricyclique fusionné ayant une activité inhibitrice d'aldose réductase |
WO2011070299A1 (fr) * | 2009-12-10 | 2011-06-16 | Sanofi-Aventis | DERIVES DE 9H-BETA-CARBOLINE (OU 9H-PYRIDINO[3,4-b]INDOLE) TRISUBSTITUES, LEUR PREPARATION ET LEUR UTILISATION THERAPEUTIQUE |
WO2011070298A1 (fr) * | 2009-12-10 | 2011-06-16 | Sanofi-Aventis | DERIVES 9H-PYRIDINO[3,4-b]INDOLE DISUBSTITUES, LEUR PREPARATION ET LEUR UTILISATION THERAPEUTIQUE |
EP2298304A3 (fr) * | 2005-04-18 | 2011-10-12 | PTC Therapeutics, Inc. | Dérivés de carboline utiles pour le traitement du cancer |
US8697662B2 (en) | 2009-05-27 | 2014-04-15 | Ptc Therapeutics, Inc. | Methods for treating Kaposi sarcoma |
US8703726B2 (en) | 2009-05-27 | 2014-04-22 | Ptc Therapeutics, Inc. | Methods for treating prostate conditions |
US9351964B2 (en) | 2009-05-27 | 2016-05-31 | Ptc Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
US10947231B2 (en) | 2009-05-27 | 2021-03-16 | Ptc Therapeutics, Inc. | Processes for the preparation of substituted tetrahydro beta-carbolines |
US11458126B2 (en) | 2017-08-01 | 2022-10-04 | Ptc Therapeutics, Inc. | DHODH inhibitor for use in treating hematologic cancers |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0705566D0 (en) * | 2007-03-23 | 2007-05-02 | Univ Dundee | Method of treating learning impairment in down's syndrome subjects |
ES2360547B1 (es) * | 2009-11-02 | 2012-07-04 | Consejo Superior De Investigaciones Científicas (Csic) | Procedimiento de obtención de los alcaloides activos de la planta medicinal peganum harmala y su uso. |
US20130165474A1 (en) * | 2010-08-17 | 2013-06-27 | Travis Dunckley | Compounds that inhibit tau phosphorylation |
EP2455378A1 (fr) * | 2010-11-03 | 2012-05-23 | Philip Morris Products S.A. | Dérivés de carbazole et de carboline, et préparation et applications thérapeutiques associées |
US9907786B2 (en) | 2014-10-21 | 2018-03-06 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof |
WO2016181220A2 (fr) * | 2015-05-13 | 2016-11-17 | Ions Pharmaceutical S.À R.L. | Compositions thérapeutiques et méthodes d'utilisation de ces compositions |
US10092550B2 (en) | 2014-10-21 | 2018-10-09 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof |
US20160106722A1 (en) * | 2014-10-21 | 2016-04-21 | Life Plus, LLC | Human therapeutic agents |
WO2016064676A1 (fr) * | 2014-10-21 | 2016-04-28 | Genzada Pharmaceuticals Llc | Agents thérapeutiques humains |
US10947253B2 (en) | 2019-08-05 | 2021-03-16 | Ankh Life Sciences Limited | Fused polycyclic dimers |
CN112716947A (zh) * | 2021-01-27 | 2021-04-30 | 新疆维吾尔自治区维吾尔医药研究所 | 从骆驼蓬中提取分离的γ-去氢骆驼蓬碱在制备抑制胃癌药物中的应用 |
CN115487184A (zh) * | 2022-09-06 | 2022-12-20 | 南昌大学 | 去氢骆驼蓬碱在制备治疗结肠癌药物中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2140797A (en) * | 1983-06-04 | 1984-12-05 | Tanabe Seiyaku Co | Tetrahydro-b-carboline derivatives |
GB2303627B (en) * | 1995-07-26 | 1997-07-09 | Arab Pharmaceutical Mfg Co Ltd | Anti-tumour platinum-harmine complex |
CN1063966C (zh) * | 1998-10-12 | 2001-04-04 | 王世渝 | 骆驼蓬制剂及制备方法 |
EP1390075B1 (fr) * | 2001-04-06 | 2012-01-18 | The University of Chicago | Induction chimiotherapeutique de l'activite du promoteur egr-1 dans la therapie genique |
-
2004
- 2004-04-30 FR FR0404646A patent/FR2869540B1/fr not_active Expired - Fee Related
-
2005
- 2005-04-29 JP JP2007510083A patent/JP2007535525A/ja active Pending
- 2005-04-29 US US11/587,852 patent/US20080069899A1/en not_active Abandoned
- 2005-04-29 EP EP05767476A patent/EP1740212A2/fr not_active Withdrawn
- 2005-04-29 WO PCT/FR2005/001082 patent/WO2005115470A2/fr active Application Filing
Non-Patent Citations (4)
Title |
---|
ISHIDA J ET AL: "Antitumor Agents 201. Cytotoxicity of Harmine and beta-Carboline Analogs" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 9, no. 23, 6 décembre 1999 (1999-12-06), pages 3319-3324, XP004183731 ISSN: 0960-894X * |
KUSURKAR R S ET AL: "Efficient one-pot synthesis of anti HIV and antitumor compounds: harman and substituted harmans" TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 44, no. 25, 16 juin 2003 (2003-06-16), pages 4761-4763, XP004426888 ISSN: 0040-4039 * |
See also references of EP1740212A2 * |
SONG Y ET AL: "Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 317, no. 1, 23 avril 2004 (2004-04-23), pages 128-132, XP004496939 ISSN: 0006-291X * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2298304A3 (fr) * | 2005-04-18 | 2011-10-12 | PTC Therapeutics, Inc. | Dérivés de carboline utiles pour le traitement du cancer |
WO2009078423A1 (fr) * | 2007-12-18 | 2009-06-25 | National University Corporation University Of Toyama | Composé tricyclique fusionné ayant une activité inhibitrice d'aldose réductase |
JP5366211B2 (ja) * | 2007-12-18 | 2013-12-11 | 国立大学法人富山大学 | アルドース還元酵素阻害活性を有する縮合三環化合物 |
US8198447B2 (en) | 2007-12-18 | 2012-06-12 | National University Corporation University Of Toyama | Fused tricyclic compound having aldose reductase inhibitory activity |
US8703726B2 (en) | 2009-05-27 | 2014-04-22 | Ptc Therapeutics, Inc. | Methods for treating prostate conditions |
US8697662B2 (en) | 2009-05-27 | 2014-04-15 | Ptc Therapeutics, Inc. | Methods for treating Kaposi sarcoma |
US9351964B2 (en) | 2009-05-27 | 2016-05-31 | Ptc Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
US10947231B2 (en) | 2009-05-27 | 2021-03-16 | Ptc Therapeutics, Inc. | Processes for the preparation of substituted tetrahydro beta-carbolines |
US11613538B2 (en) | 2009-05-27 | 2023-03-28 | Ptc Therapeutics, Inc. | Method of inhibiting or reducing a viral infection |
FR2953837A1 (fr) * | 2009-12-10 | 2011-06-17 | Sanofi Aventis | Derives 9h-pyridino[3,4-b]indole disubstitues, leur preparation et leur utilisation therapeutique |
FR2953838A1 (fr) * | 2009-12-10 | 2011-06-17 | Sanofi Aventis | Derives de 9h-beta-carboline (ou 9h-pyridino[3,4-b]indole) trisubstitues, leur preparation et leur utilisation therapeutique |
WO2011070298A1 (fr) * | 2009-12-10 | 2011-06-16 | Sanofi-Aventis | DERIVES 9H-PYRIDINO[3,4-b]INDOLE DISUBSTITUES, LEUR PREPARATION ET LEUR UTILISATION THERAPEUTIQUE |
WO2011070299A1 (fr) * | 2009-12-10 | 2011-06-16 | Sanofi-Aventis | DERIVES DE 9H-BETA-CARBOLINE (OU 9H-PYRIDINO[3,4-b]INDOLE) TRISUBSTITUES, LEUR PREPARATION ET LEUR UTILISATION THERAPEUTIQUE |
US11458126B2 (en) | 2017-08-01 | 2022-10-04 | Ptc Therapeutics, Inc. | DHODH inhibitor for use in treating hematologic cancers |
Also Published As
Publication number | Publication date |
---|---|
EP1740212A2 (fr) | 2007-01-10 |
WO2005115470A3 (fr) | 2007-03-22 |
US20080069899A1 (en) | 2008-03-20 |
JP2007535525A (ja) | 2007-12-06 |
FR2869540B1 (fr) | 2008-05-16 |
FR2869540A1 (fr) | 2005-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005115470A2 (fr) | COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS | |
EP3229810B1 (fr) | Analogues d'éther phospholipidique utilisés en tant que véhicules de médicament ciblant le cancer | |
EP1323423B1 (fr) | Préparation combinée contenant un dérivé morpholinyl d'anthracycline et un inhibiteur de la topoisomerase II | |
TW200540179A (en) | Macrolides | |
TW201004619A (en) | Methods and compositions for therapeutic treatment | |
US20120219568A1 (en) | Epidithiodioxopiprazines and uses thereof in treating cancer | |
JP2015512398A (ja) | Pfkfb2阻害剤および抗癌治療法としての使用方法 | |
EP3429568A1 (fr) | Composition pharmaceutique utilisée pour le traitement thérapeutique du cancer et ses complications | |
JP5640019B2 (ja) | 糖尿病及び肥満症を治療するためのプテロシン化合物の使用 | |
Appendino | Ingenane diterpenoids | |
US20140120181A1 (en) | Composition comprising phosphatidylcholine as an active ingredient for attenuating toxicity of anticancer agent | |
WO2006116897A1 (fr) | Diterpenes provenant de euphorbia kansui et leur utilisation | |
TW201136598A (en) | Protoilludance norsesquiterpenoid esters and uses thereof | |
Konno | Biologically active components of poisonous mushrooms | |
JPH03500166A (ja) | チトカラシンの精製方法および組成物 | |
WO2018055136A1 (fr) | Utilisation des harringtonines dans le traitement du cancer du sein, notamment triple-négatif | |
JPS6355485B2 (fr) | ||
JP2021512961A (ja) | ミトコンドリア障害を処置するための方法 | |
KR20130122767A (ko) | 가르시놀, 사이클로덱스트린의 착물 및 이의 제조방법 | |
JP2002509532A (ja) | アルグラビン(arglabin)およびアルグラビン誘導体の薬学的組成物 | |
TW201420608A (zh) | 抗癌和抗肥胖之環狀肽藥劑 | |
KR100646574B1 (ko) | 항암제로 유발되는 독성의 억제제 및 이를 함유하는 항암제조성물 | |
WO2020174486A1 (fr) | Isolement et caractérisation d'un composé anticancéreux issu de sesuvium portulacastrum (l) l. | |
FR2746645A1 (fr) | Compositions de triterpenes a activite anticancereuse | |
KR20220062363A (ko) | 암 표적성 약물 전달체로서의 인지질 에테르 접합체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005767476 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007510083 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005767476 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11587852 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 11587852 Country of ref document: US |